Kinase Inhibitor Scaffold and Property Comparison Tool
Compare the chemical graphs and physicochemical descriptors of approved ATP-competitive kinase inhibitors in the browser. The workspace opens erlotinib in the comparison section, where gefitinib or another inhibitor from the library is added beside it. This reference shows how central hinge-binding heterocycles and solvent-front solubilising tails tune molecular weight, Crippen logP, TPSA and basicity.
Opens erlotinib (CHEMBL553) from the shipped ChEMBL 37 approved-drug library. Gefitinib (CHEMBL939), a closely related EGFR 4-anilinoquinazoline with a different headgroup and tail, is the suggested comparator; the address cannot pre-load a second molecule, so it is added in the comparison section.
Deconstruct hinge binders, gatekeeper headgroups and solvent tails
Most ATP-competitive kinase inhibitors follow a modular architecture: a nitrogen-containing heteroaromatic core (such as a quinazoline, aminopyrimidine, pyrrolopyrimidine or indolinone) mimics the adenine ring of ATP at the hinge region; a substituted aryl or alkynyl headgroup projects toward the gatekeeper residue; and a polar or basic tail extends toward the solvent-exposed entrance of the cleft.
Adding gefitinib beside erlotinib (or imatinib CHEMBL941 or dasatinib CHEMBL1421 instead) in the workbench lets you inspect how modifying the peripheral tail or swapping the central heterocycle shifts TPSA, Crippen logP, rotatable bonds and Fsp3.
Connect kinase scaffold properties to target mutations and stock preparation
When moving from structural comparison to biochemical experiments, link the compound identity to the exact target sequence variant in the protein workspace (such as wild-type EGFR versus T790M or L858R) and verify whether the tested reagent vial is a free base, hydrochloride or mesylate salt.
Equations and variables
Descriptor shift across a scaffold or tail comparison
ΔP = Panalogue − Preference
- Panalogue, Preference
- Calculated descriptor value for the comparator and reference kinase inhibitor
- ΔP
- Signed difference in MW, cLogP, TPSA, HBD, HBA, Nrot or Fsp3
Partition coefficient definition
log P = log10([solute]octanol/[solute]water)
- P
- Partition coefficient of the neutral species under the defined conditions
- [solute]
- Equilibrium concentration in the indicated phase (mol/L)
Topological polar surface area
TPSA = Σ Ai
- Ai
- Polar fragment contribution assigned by the descriptor method (Ų)
- TPSA
- Topological estimate from the represented molecular graph (Ų)
Scope and limitations
- Whole-molecule descriptors compare the neutral parent graphs and do not model the pKa of morpholine or piperazine solubilising tails at physiological or lysosomal pH.
- Two kinase inhibitors with similar TPSA and cLogP can bind completely different conformational states (such as Type I DFG-in vs Type II DFG-out) and display distinct kinome selectivity profiles.
- The workbench does not perform 3D hinge-hydrogen-bond pharmacophore alignment or kinome tree selectivity prediction.
Sources and provenance
- RDKit descriptor implementation and versioned reference checksBSD-3-Clause
Method implementation; computed molecular properties are estimates.
- ChEMBL 37 parent structures in the shipped compound libraryCC BY-SA 3.0; share-alike
Existing library capture: 28 September 2026. Preserve attribution when redistributing its rows.
- Wildman and Crippen: atomic contributions to molecular propertiesCited method; no reproduced article data
- Ertl, Rohde and Selzer: fast calculation of molecular polar surface areaCited method; no reproduced article data
- Attwood et al.: trends in the discovery of small-molecule kinase inhibitors (Nature Reviews Drug Discovery)Cited review; physicochemical profiles of approved kinase inhibitors
Technical questions
How do the structural differences between erlotinib and gefitinib affect their computed descriptors?
Both share a 4-anilinoquinazoline core that forms hydrogen bonds with the EGFR kinase hinge region. Erlotinib carries a meta-ethynyl aniline headgroup and two symmetrical methoxyethoxy tails, whereas gefitinib carries a 3-chloro-4-fluoroaniline headgroup, one methoxy group and a basic morpholinopropoxy tail. Those changes shift molecular weight, rotatable bonds, Fsp3 and ionisation behaviour.
Why do many kinase inhibitors attach a piperazine or morpholine ring at the solvent-exposed rim?
The heteroaromatic hinge-binding core and hydrophobic back-pocket group are typically flat and poorly soluble. Appending a saturated nitrogen heterocycle pointing into the aqueous solvent channel increases Fsp3, disrupts crystal packing and introduces a weakly basic centre that improves aqueous dissolution.
Can descriptor similarity distinguish a Type I from a Type II kinase inhibitor?
Not reliably by itself, although Type II DFG-out inhibitors (such as imatinib, CHEMBL941) often have higher molecular weight, an extra amide or urea linker and an additional hydrophobic tail to reach the allosteric back pocket compared with compact Type I inhibitors.
Connected workflows
- EGFR sequence and structure inspection
View the EGFR ectodomain in 3D (4UV7) and see why the T790M gatekeeper lies outside it.
- Chemical structure and canonical SMILES
Compare the imatinib Type II kinase inhibitor scaffold in the sketcher.
- 4PL IC50 curve fitting
Fit biochemical or cellular inhibition curves for kinase inhibitor series.